- Home
- USEA vs SNGX Comparison
USEA vs SNGX Comparison
Compare USEA & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- SNGX
- Stock Information
- Founded
- USEA 2004
- SNGX 1987
- Country
- USEA Greece
- SNGX United States
- Employees
- USEA N/A
- SNGX N/A
- Industry
- USEA Marine Transportation
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- SNGX Health Care
- Exchange
- USEA Nasdaq
- SNGX Nasdaq
- Market Cap
- USEA 15.6M
- SNGX 13.8M
- IPO Year
- USEA N/A
- SNGX 1987
- Fundamental
- Price
- USEA $1.49
- SNGX $1.36
- Analyst Decision
- USEA
- SNGX Strong Buy
- Analyst Count
- USEA 0
- SNGX 1
- Target Price
- USEA N/A
- SNGX $6.00
- AVG Volume (30 Days)
- USEA 24.0K
- SNGX 338.4K
- Earning Date
- USEA 11-11-2025
- SNGX 11-07-2025
- Dividend Yield
- USEA 2.67%
- SNGX N/A
- EPS Growth
- USEA N/A
- SNGX N/A
- EPS
- USEA N/A
- SNGX N/A
- Revenue
- USEA $42,625,000.00
- SNGX N/A
- Revenue This Year
- USEA N/A
- SNGX N/A
- Revenue Next Year
- USEA N/A
- SNGX N/A
- P/E Ratio
- USEA N/A
- SNGX N/A
- Revenue Growth
- USEA N/A
- SNGX N/A
- 52 Week Low
- USEA $1.00
- SNGX $1.09
- 52 Week High
- USEA $2.35
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- USEA 31.42
- SNGX 37.52
- Support Level
- USEA $1.50
- SNGX $1.30
- Resistance Level
- USEA $1.63
- SNGX $1.61
- Average True Range (ATR)
- USEA 0.05
- SNGX 0.09
- MACD
- USEA -0.02
- SNGX -0.00
- Stochastic Oscillator
- USEA 18.75
- SNGX 22.98
About USEA United Maritime Corporation
United Maritime Corp is an international shipping company. It is engaged in seaborne transportation services. The group currently operates a fleet of seven dry bulk vessels, comprising three Panamax, two Capesize and two Kamsarmax vessels with an aggregate cargo-carrying capacity of approximately 750,758 dwt.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).